BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy. ...read more
BLINCYTO® is given by a continuous intravenous (IV) infusion. This means the medicine goes into your body through a vein. This happens for a 4-week period.1,2
The dosing of BLINCYTO® occurs in cycles. Here’s how a cycle works:1
One cycle is 4 weeks of continuous infusion followed by 2 weeks without infusion.1
In the study of BLINCYTO® for MRD, most people were given 1 or 2 cycles.3 Your doctor will decide how long you will need to stay on treatment.
BLINCYTO® treatment starts in the hospital to make sure that it is safe for you and to prevent and manage any side effects that may occur.1
Afterward, your doctor will decide if you can get the rest of your treatment at home, if that is right for you. Or your doctor may refer you to an outpatient clinic or an infusion center to manage your treatment.
*The 7-day infusion is not recommended for patients weighing less than 22 kg.
If it feels overwhelming to receive BLINCYTO® away from the hospital, you have support options. Your health care team may be able to help make sure you are prepared. Here are some notes about receiving BLINCYTO® at home:
This calendar helps you keep track of scheduled appointments and bag changes.
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
What should I avoid while receiving BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy.
The approval of BLINCYTO® in these patients is based on a study that measured response rate and duration of response. There are ongoing studies to confirm clinical benefit.
What is the most important information I should know about BLINCYTO®?
References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. National Cancer Institute. NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed October 8, 2019. 3. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522-1531. 4. BLINCYTO® (blinatumomab) medication guide, Amgen.